SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea
· Delayed Price · Currency is KRW 98,100
-4,800 (-4.66%)
At close: Mar 9, 2026
SK Biopharmaceuticals Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 7,682,530 | 8,700,602 | 7,862,650 | 5,646,385 | 7,612,048 | 13,234,939 | Upgrade
|
| Market Cap Growth | -21.33% | 10.66% | 39.25% | -25.82% | -42.48% | - | Upgrade
|
| Enterprise Value | 7,492,395 | 8,637,734 | 7,807,605 | 5,442,304 | 7,267,516 | 12,840,764 | Upgrade
|
| Last Close Price | 98100.00 | 111100.00 | 100400.00 | 72100.00 | 97200.00 | 169000.00 | Upgrade
|
| PE Ratio | 23.97 | 36.14 | - | - | 117.39 | - | Upgrade
|
| Forward PE | 29.06 | 73.81 | - | - | - | - | Upgrade
|
| PS Ratio | 11.37 | 15.89 | 22.16 | 22.94 | 18.18 | 509.06 | Upgrade
|
| PB Ratio | 11.14 | 15.16 | 24.50 | 17.84 | 17.14 | 34.92 | Upgrade
|
| P/TBV Ratio | 11.55 | 16.24 | 29.59 | 18.86 | 17.90 | 36.83 | Upgrade
|
| P/FCF Ratio | 53.70 | 93.05 | - | - | - | - | Upgrade
|
| P/OCF Ratio | 52.55 | 91.68 | - | - | - | - | Upgrade
|
| EV/Sales Ratio | 11.09 | 15.77 | 22.00 | 22.11 | 17.36 | 493.89 | Upgrade
|
| EV/EBITDA Ratio | 42.69 | 75.93 | - | - | 68.18 | - | Upgrade
|
| EV/EBIT Ratio | 47.40 | 89.66 | - | - | 76.53 | - | Upgrade
|
| EV/FCF Ratio | 52.38 | 92.38 | - | - | - | - | Upgrade
|
| Debt / Equity Ratio | 0.07 | 0.32 | 0.56 | 0.49 | 0.04 | 0.05 | Upgrade
|
| Debt / EBITDA Ratio | 0.23 | 1.62 | - | - | 0.15 | - | Upgrade
|
| Debt / FCF Ratio | 0.35 | 1.97 | - | - | - | - | Upgrade
|
| Net Debt / Equity Ratio | -0.30 | -0.24 | -0.20 | -0.47 | -0.72 | -0.97 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.96 | -1.23 | 2.84 | 1.27 | -2.99 | 1.62 | Upgrade
|
| Net Debt / FCF Ratio | -1.45 | -1.50 | 0.65 | 0.91 | 3.28 | 1.67 | Upgrade
|
| Asset Turnover | 0.75 | 0.62 | 0.51 | 0.38 | 0.73 | 0.08 | Upgrade
|
| Inventory Turnover | 0.31 | 0.40 | 0.35 | 0.53 | 0.60 | 0.13 | Upgrade
|
| Quick Ratio | 1.84 | 1.26 | 1.47 | 2.28 | 2.64 | 5.67 | Upgrade
|
| Current Ratio | 2.43 | 1.64 | 2.02 | 2.99 | 3.18 | 6.16 | Upgrade
|
| Return on Equity (ROE) | 58.15% | 50.72% | -11.10% | -36.66% | 15.75% | -135.18% | Upgrade
|
| Return on Assets (ROA) | 13.73% | 6.84% | -3.38% | -12.53% | 10.38% | -46.83% | Upgrade
|
| Return on Invested Capital (ROIC) | 41.79% | 27.85% | -17.66% | -89.60% | 127.86% | -2063.82% | Upgrade
|
| Return on Capital Employed (ROCE) | 25.90% | 15.00% | -7.80% | -26.20% | 19.20% | -55.70% | Upgrade
|
| Earnings Yield | 4.17% | 2.77% | -0.42% | -2.47% | 0.85% | -1.87% | Upgrade
|
| FCF Yield | 1.86% | 1.07% | -1.23% | -2.92% | -1.28% | -1.68% | Upgrade
|
| Buyback Yield / Dilution | - | - | - | - | -9.12% | -10.41% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.